ACT Capital Management Exits Structure Therapeutics Position Amid Stock's 47% Rise
Structure Therapeutics' stock has risen 47% year-to-date, but ACT Capital Management sold its entire $2.63 million stake in the first quarter of 2026. The fund reported a net position decrease of $2.68 million due to both sales and price changes.
Tickers: $GPCR
Topics: portfolio changes SEC filings stock sales